A prospective, controlled, randomized, open-label, single-center study for eramyd in the treatment of active sjogren's syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022696

Enrollment

Unknown

Registered

2019-04-22

Start date

2019-06-01

Completion date

Unknown

Last updated

2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sjogren syndrome

Interventions

experimental group :Iguratimod 25mg bid po

control group:hydroxychloroquine 0.2-0.4g/d+prednison0.2-0.5mg/kg.d

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) it meets the international classification standard of sjogren's syndrome in 2002; (2) aged 18-70 years, male or female; (3) ESSDAI 4 points; (4) the patient signed the informed consent and obtained the approval from the hospital ethics committee; (5) involvement of the blood system or lungs or liver.

Exclusion criteria

Exclusion criteria: (1) those who are in the remission stage of primary sjogren's syndrome; (2) patients with severe heart failure, respiratory failure, liver dysfunction and renal failure; (3) combined with systemic or local severe infection; (4) have a history of multiple drug allergies; (5) lactating pregnant women.

Design outcomes

Primary

Measure	Time frame
ESSDAI grade;IgG?IgM?IgA of serum;C3?C4 of serum;	—

Countries

China

Contacts

Public ContactJianping Tang

Shanghai tongji hospital

tangjp6512@126.com+86 18964869005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026